Business context and reporting period
The supplied filing is Immudyne, Inc.’s unaudited Form 10-Q for the quarter ended June 30, 2013—not a LifeMD, Inc. filing. Immudyne makes and sells yeast beta-glucan nutraceutical and cosmetic products, focusing on oral and topical products for healthcare professionals, distributors, and direct consumers.
Financial performance and position
- Second quarter: Sales were $322,903, up 42% year over year. Gross profit was $257,235 (80% gross margin), versus $123,764 (54%) a year earlier. Operating loss was $20,154, compared with $215,699; net loss was $15,854, versus $186,842.
- First half: Sales were $553,161, up 36%. Gross profit was $418,398 (76% gross margin), versus $227,139 (56%). Operating expenses rose 6% to $509,339; operating loss narrowed to $90,941 from $251,525, and net loss narrowed to $57,341 from $215,135.
- Cash flow: First-half operating cash use was $37,873, compared with $78,785 in 2012. Stock-option exercises provided $50,000, producing a $12,127 net increase in cash. Cash at June 30 was $111,057.
- Liquidity and balance sheet: Current assets were $332,615 and accounts payable and accrued expenses were $242,667; the balance sheet also presents a $39,000 deferred tax liability. Total liabilities were $281,667 and stockholders’ equity was $180,158. No borrowing balance is separately shown on the balance sheet.
- Per-share and share data: Basic and diluted loss per share was reported as $0.00 for both the quarter and first half of 2013. There were 29,409,973 common shares outstanding on August 14, 2013.
Changes versus the prior comparable period
Management attributed sales growth to increased demand for topical-use products. Lower laboratory and manufacturing costs helped lift gross margins. Quarterly operating expenses declined, including lower professional fees due to reduced legal costs; first-half compensation expense increased, partly due to the newly hired Chief Marketing Officer. The prior-year comparisons included $25,000 of license-fee income in the second quarter and $31,161 of other income for the first half, making the reported improvement in net loss larger than the operating-loss improvement alone.
Outlook, risks, contingencies, and unusual items
- Funding and going concern: The filing says the accumulated deficit was approximately $8 million and operating cash flow was negative, raising substantial doubt about the Company’s ability to continue as a going concern. Management expected to need additional capital for 2013 and planned to rely on higher sales, equity issuance, or debt financing; success and terms were not assured.
- Business plans: Management described a 15-month sales and marketing plan and plans for new products, but gave no quantified revenue or earnings guidance. It expected marketing and selling, general, and administrative costs to rise as the business expanded.
- Customer concentration: One customer represented 83% of second-quarter sales and 81% of first-half sales; that customer was 78% of receivables at June 30. A second customer represented 9% of quarterly sales and 10% of first-half sales.
- Royalties and commitments: An existing skin-care royalty requires 8% of covered sales, subject to a stated $227,175 cap. About $131,000 was accrued in payables and approximately $80,000 of commitment remained; the President held a 60% interest and had deferred payment. A new consultant agreement calls for 2% of defined sales; none had accrued by June 30. Future minimum plant lease payments totaled $121,919 through 2016.
- Controls and other risks: Management concluded disclosure controls were ineffective and identified material weaknesses involving segregation of duties, written accounting/reporting procedures, computer-system access and recovery, and the lack of a whistleblower policy. Risks discussed include financing availability, customer concentration, product regulation, intellectual-property protection, and potential dilution or debt constraints from raising capital. Management reported no known material legal proceeding and no subsequent event requiring disclosure.
Important facts for investors to verify
- Confirm the issuer identity: the filing names Immudyne, Inc., whereas the request metadata names LifeMD, Inc.
- Reconcile liquidity disclosures: management reports net working capital of $89,948 and a 1.4-to-1 current ratio, figures that appear to exclude the $39,000 deferred tax liability shown among current liabilities. Including that liability, the balance-sheet current-asset excess is $50,948 and the ratio is approximately 1.18-to-1.
- Assess whether the Company can raise the capital management says it needs and whether sales growth can reduce cash burn.
- Evaluate the dependence on the largest customer and the related receivable concentration.
- Review royalty accruals, deferred payments, and related-party interests, along with remediation of the disclosed control weaknesses.